Gustavo Villoldo

@GustavoVillold4

Urologist, Uro-Oncology Unit, Co-director of UroOnco/Lap Fellow, Instituto Alexander Fleming (IAF), Buenos Aires, Argentina.

Ciudad Autónoma de Buenos Aire
Vrijeme pridruživanja: kolovoz 2019.
25 fotografija ili videozapisa Fotografije i videozapisi

Tweetovi

Blokirali ste korisnika/cu @GustavoVillold4

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @GustavoVillold4

  1. proslijedio/la je Tweet
    1. velj

    Bladder sparing study (NCT03697850) phase II trial investigating atezolizumab as maintenance therapy in MIBC patients treated with chemo-radiotherapy is enrolling

    1 reply 16 proslijeđenih tweetova 22 korisnika označavaju da im se sviđa
    Poništi
  2. proslijedio/la je Tweet
    prije 20 sati

    Performance of PCA3 and TMPRSS2: ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study . article on UroToday >

    3 proslijeđena tweeta 7 korisnika označava da im se sviđa
    Poništi
  3. proslijedio/la je Tweet
    prije 21 sat

    PSA Dynamics Predict Metastatic Castration-Sensitive Prostate Cancer Treatment Outcomes

    2 proslijeđena tweeta 2 korisnika označavaju da im se sviđa
    Poništi
  4. proslijedio/la je Tweet
    2. velj
    Odgovor korisnicima

    😂😂 Thanks Gustavo!! The pleasure is mine to share experience with old friends and new oncologists in training!

    1 proslijeđeni tweet 6 korisnika označava da im se sviđa
    Poništi
  5. 2. velj

    Congrats!!!! ⁦⁩ for this clinical trial!!! It is an honor working in the same place you’ve done your training!!!! Argentinian medical society should be proud of this achievement!!!! ⁦⁩

    1 reply 10 proslijeđenih tweetova 28 korisnika označava da im se sviđa
    Poništi
  6. 2. velj

    INTERESTING TRIAL trying to determine if adjuvant RTP can benefit patients post cystectomy to achive local control. Discussion must include not just an “yes or not answer” but also fields and dosis!!

    Still an important question in the context of negative data from IMVIGOR 010 study
    Poništi
  7. proslijedio/la je Tweet
    1. velj

    Clinical implications of the trial cabazitaxel vs Abi or Enza in pts previously treated w/ docetaxel & had progression within 12 mths while receiving the alternative inhibitor.

    5 proslijeđenih tweetova 12 korisnika označava da im se sviđa
    Poništi
  8. proslijedio/la je Tweet
    1. velj

    “La Oficina de Investigación te invita a participar del curso en línea sobre Metodología de la Investigación Científica en Urología “

    1 reply 15 proslijeđenih tweetova 34 korisnika označavaju da im se sviđa
    Poništi
  9. 31. sij

    BALANCE trial!! we were waiting for this kind of modern trials!!..!!! examining the rol of salvage with or without new anti androgen drugs ()

    It is with mixed emotions to share that NRG GU006 (BALANCE) trial will soon close to accrual. It accrued 4 times ahead of schedule thanks to all of the support from over 300 centers who opened it and nearly 90 centers who were able to enroll at least 1 patient.
    Prikaži ovu nit
    1 proslijeđeni tweet 4 korisnika označavaju da im se sviđa
    Poništi
  10. 31. sij

    was the last drug in the M0 CRPC arena approved and NOW!! It’s the first one in achieving OS!! Witch one is going to win this race?

    5 proslijeđenih tweetova 12 korisnika označava da im se sviđa
    Poništi
  11. 31. sij

    IO is now spreading everywhere!!. This combining chemo/RTP + could help in the near future to conserve more

    Several years in the making, I'm thrilled that this potentially practice changing trial will activate soon. IO is challenging RC in NMIBC, now on to MIBC!
    1 proslijeđeni tweet 4 korisnika označavaju da im se sviđa
    Poništi
  12. proslijedio/la je Tweet
    29. sij

    “ Desde la Oficina de Investigación CAU ponemos a disposición las Revistas Iberomericanas de Urología con acceso abierto”

    22 proslijeđena tweeta 42 korisnika označavaju da im se sviđa
    Poništi
  13. proslijedio/la je Tweet
    29. sij

    Felicitaciones 👏👏👏 ! Orgullo 🇦🇷. Gran aporte para el manejo del

    1 reply 6 proslijeđenih tweetova 17 korisnika označava da im se sviđa
    Poništi
  14. 26. sij

    Are we thinking straight? Is the equation between cost and benefits balanced in CIS ? Is going to change the management in this population or just will be reserved to few patients, very selected unfit for

    ODAC Cautiously Backs Keytruda in Early Bladder Cancer - it was a difficult decision but in the end, we decided that the response rate had an acceptable risk/benefit ratio
    Poništi
  15. 26. sij

    Another blow to : IMvigor010 study evaluating as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in patients with

    1 korisnik označava da mu se sviđa
    Poništi
  16. 23. sij

    Another Knocking down myths presentation!!!!: IV contrast and risk of AKI. So, is IV contrast safer than we think?

    Risk of contrast-induced AKI: a myth?
    3 proslijeđena tweeta 5 korisnika označava da im se sviđa
    Poništi
  17. 20. sij

    PSA vs. MRI for assessing oncological outcomes after HIFU focal therapy for localized ⁦⁩

    1 reply 5 korisnika označava da im se sviđa
    Poništi
  18. proslijedio/la je Tweet
    18. sij

    A lot to do in the area of oligometastatic - comprehensive insight by 👌

    3 proslijeđena tweeta 6 korisnika označava da im se sviđa
    Poništi
  19. proslijedio/la je Tweet
    20. sij

    Prolonged sitting time and low physical activity levels are tied to higher incidence of lower urinary tract symptoms (LUTS) in men, according to a study published online in BJU International.

    2 proslijeđena tweeta 5 korisnika označava da im se sviđa
    Poništi
  20. proslijedio/la je Tweet
    17. sij

    Take home messages for the BCG-shortage at

    1 reply 11 proslijeđenih tweetova 22 korisnika označavaju da im se sviđa
    Poništi

@GustavoVillold4 još nije objavio nijedan Tweet.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·